Concepedia

Jeffrey Cohen

JC

Statistics

Publications

14

Citations

4.2K

H-Index

13

Active since

1999

Affiliations

Cleveland Clinic(Current)

University of Cambridge

Charles University

Heinrich Heine University Düsseldorf

Queen Mary University of London

Jeffrey Cohen is an author at Cleveland Clinic specializing in medicine, immunology, and clinical trials.

Top concepts

Publications per year

1999–2020

14

Publications

14

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

, , +8

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

, , +4

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Jeffrey Cohen et al. · New England Journal of Medicine · 2020 · 650 citations · Full text

Alemtuzumab CARE-MS II 5-year follow-up

Alasdair Coles, Jeffrey Cohen, Edward Fox et al. · Neurology · 2017 · 273 citations · Full text

Alemtuzumab CARE-MS I 5-year follow-up

Eva Havrdová, Douglas L. Arnold, Jeffrey Cohen et al. · Neurology · 2017 · 222 citations · Full text

1–5 of 14